Share this article on:

Invasive Haemophilus influenzae Type b (Hib) Infections in Children with Cancer in the Era of Infant Hib Immunization Programs (1991–2014): A Report from the Canadian Immunization Monitoring Program Active

McNair, Joanne1; Smith, Alyssa2; Bettinger, Julie, A.3; Vaudry, Wendy4; Tan, Ben5; Desai, Shalini6; Halperin, Scott, A.2,7; Top, Karina, A.2,7*for the Canadian Immunization Monitoring Program Active (IMPACT) Investigators

The Pediatric Infectious Disease Journal: December 1, 2017 - Volume Publish Ahead of Print - Issue - p
doi: 10.1097/INF.0000000000001850
Brief Reports: PDF Only

We studied the epidemiology of Haemophilus influenzae type b (Hib) infections among children with cancer admitted to Canadian pediatric hospitals. From 1991-2014, 13 cases among children with cancer were identified through active surveillance. Average age was 6.7 years. Six of 7 cases eligible for infant immunization were age-appropriately immunized (vaccine failures). Children with cancer may benefit from booster Hib immunization.

1Faculty of Medicine, Dalhousie University, Halifax, NS, Canada

2Department of Pediatrics, Dalhousie University, Halifax, NS, Canada

3University of British Columbia and Vaccine Evaluation Center, BC Children’s Hospital, Vancouver, BC, Canada

4University of Alberta, Stollery Children’s Hospital, Edmonton, AB, Canada

5University of Saskatchewan, Royal University Hospital, Saskatoon, SK, Canada

6Public Health Agency of Canada, Toronto, Canada

7Canadian Center for Vaccinology, IWK Health Centre, Halifax, NS, Canada

Conflicts of interest: KAT has received research support from Pfizer and GlaxoSmithKline and consultancy fees from Pfizer outside the submitted work. SAH has received grants from Pfizer and GlaxoSmithKline outside the submitted work. The other authors have no disclosures.

Funding: This surveillance activity is conducted as part of the Canadian Immunization Monitoring Program Active (IMPACT), a national surveillance initiative managed by the Canadian Paediatric Society and conducted by the IMPACT network of pediatric investigators on behalf of the Public Health Agency of Canada’s Centre for Immunization and Respiratory Infectious Diseases. KAT is supported by an Investigatorship Award from the IWK Health Centre. JAB is a Michael Smith Foundation for Health Research Scholar.

Acknowledgements: The authors gratefully acknowledge the expert assistance of the Monitor Liaison (Heather Samson), IMPACT nurse monitors, staff of the IMPACT Data Center (Kim Marty) and Melanie Laffin (Canadian Paediatric Society).

*Corresponding author: Dr. Karina Top, IWK Health Centre, 4th Floor Goldbloom RCC Pavilion, 5850/5980 University Ave, Halifax, NS, Canada B3K 6R8; Tel: 1-902-470-8141; Fax: 1-902-470-7232; Email:

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.